Current Report Filing (8-k)
September 22 2017 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
September 22, 2017
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-35737
(Commission
File Number)
|
|
94-3306718
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 7.01.
|
Regulation FD Diclosure.
|
The Company has received
some shareholder inquiries about whether the Company will be presenting at the SMi conference in London on September 27-28, 2017.
While anticipating the disclosure of interim blinded data from the Company’s Phase 3 trial of DCVax®-L for Glioblastoma,
the Company will not be presenting at this year’s SMi conference. SMi will be posting this same information on their
website and in the conference program.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
Date: September 22, 2017
|
By:
|
/s/ Les Goldman
|
|
Name:
|
Les Goldman
|
|
Title:
|
Senior Vice President
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Oct 2023 to Oct 2024